GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » Inventories, Other

Thiogenesis Therapeutics (TSXV:TTI) Inventories, Other : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Thiogenesis Therapeutics's other inventories for the quarter that ended in Dec. 2024 was C$0.00 Mil.


Thiogenesis Therapeutics Inventories, Other Historical Data

The historical data trend for Thiogenesis Therapeutics's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Thiogenesis Therapeutics Inventories, Other Chart

Thiogenesis Therapeutics Annual Data
Trend Dec19 Dec20 Feb21 Feb22 Dec23 Dec24
Inventories, Other
Get a 7-Day Free Trial - - - - -

Thiogenesis Therapeutics Quarterly Data
Dec19 Sep20 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Thiogenesis Therapeutics Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Thiogenesis Therapeutics Business Description

Traded in Other Exchanges
Address
4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6
Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.
Executives
Vincent P. Stanton 10% Security Holder